https://pro.thestreet.com/thefly-newsbreaks/goss-gossamer-bio-initiated-with-bullish-view-at-oppenheimer
Gossamer Bio initiated with bullish view at Oppenheimer | TheStreet Pro
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's...
gossamer bioinitiatedbullishviewoppenheimer
https://www.businesswire.com/news/home/20230808193999/en/Gossamer-Bio-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatme...
gossamer biosecond quarter
https://markets.businessinsider.com/news/stocks/gossamer-bio-reports-q4-revenue-9-4m-consensus-7-0m-1034475852
Gossamer Bio reports Q4 revenue $9.4M, consensus $7.0M | Markets Insider
16:03 EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and oppo...
gossamer bio
https://www.gossamerbio.com/
Home - Gossamer Bio
Jun 23, 2025 - Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment...
gossamerbio